Insider · CIK 0001578965
Adam Koppel
Files at KLRA (Kailera Therapeutics, Inc.). First filing Apr 20, 2026, latest Apr 20, 2026.
Adam Koppel files SEC Form 4 as director and 10% owner at KLRA (Kailera Therapeutics, Inc.). Since Apr 20, 2026, Adam Koppel has reported 1 open-market buy worth $25M and 0 open-market sells worth $0, the latest filed on Apr 20, 2026.
A track record needs three past buys with six months of prices behind them; Adam Koppel has 0, so none is measured yet.
The newest scored trade: bought $25M of KLRA on Apr 20, 2026, filed Apr 20, 2026, scored 68 (notable). In the last 12 months: 1 buy worth $25M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KLRA: Kailera Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | Kailera Therapeutics, Inc. | $25M 1,562,500 shares | +7% | 0% from low-5% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +16,875,000 | - | - | 16,875,000 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +4,145,768 | - | - | 21,020,768 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,562,500 | $16.00 | $25M | 22,583,268 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See footnotes | -16,875,000 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -4,145,768 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
Questions about Adam Koppel
Answered from the filings on this page, as of the latest one.
Is Adam Koppel buying or selling?
In the last 12 months Adam Koppel reported 1 open-market buy worth $25M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $25M of KLRA on Apr 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Adam Koppel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Adam Koppel has 0.
Where does Adam Koppel file Form 4?
Adam Koppel has filed Form 4 at KLRA (Kailera Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.